|
EP2734621B1
(en)
|
2011-07-22 |
2019-09-04 |
President and Fellows of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
|
US20150017136A1
(en)
*
|
2013-07-15 |
2015-01-15 |
Cellectis |
Methods for engineering allogeneic and highly active t cell for immunotherapy
|
|
US20230050345A1
(en)
*
|
2013-05-13 |
2023-02-16 |
Cellectis |
Methods for engineering allogeneic and highly active t cell for immunotheraphy
|
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
|
US9340800B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
Extended DNA-sensing GRNAS
|
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
|
US9322037B2
(en)
|
2013-09-06 |
2016-04-26 |
President And Fellows Of Harvard College |
Cas9-FokI fusion proteins and uses thereof
|
|
JP2016536021A
(ja)
|
2013-11-07 |
2016-11-24 |
エディタス・メディシン，インコーポレイテッド |
ＣＲＩＳＰＲ関連方法および支配ｇＲＮＡのある組成物
|
|
US10357515B2
(en)
*
|
2013-11-22 |
2019-07-23 |
Cellectis |
Method for generating batches of allogeneic T-cells with averaged potency
|
|
US20150165054A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting caspase-9 point mutations
|
|
EP3808410A1
(en)
*
|
2013-12-20 |
2021-04-21 |
Cellectis |
Method of engineering multi-input signal sensitive t cell for immunotherapy
|
|
CA2943008C
(en)
|
2014-03-19 |
2021-03-30 |
Cellectis |
Cd123 specific chimeric antigen receptors for cancer immunotherapy
|
|
CA2956224A1
(en)
|
2014-07-30 |
2016-02-11 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
|
AU2015339743C1
(en)
|
2014-10-31 |
2021-04-22 |
The Trustees Of The University Of Pennsylvania |
Altering gene expression in modified T cells and uses thereof
|
|
US20180002435A1
(en)
|
2015-01-26 |
2018-01-04 |
Cellectis |
mAb-DRIVEN CHIMERIC ANTIGEN RECEPTOR SYSTEMS FOR SORTING/DEPLETING ENGINEERED IMMUNE CELLS
|
|
AU2016214301B2
(en)
*
|
2015-02-06 |
2022-05-19 |
Cellectis |
Primary hematopoietic cells genetically engineered by slow release of nucleic acids using nanoparticles
|
|
KR20170137079A
(ko)
|
2015-03-11 |
2017-12-12 |
셀렉티스 |
그것들의 지속을 증가시키기 위한 동종이계 t 세포의 조작 및/또는 환자들 내로 이식 방법들
|
|
CN115537396A
(zh)
*
|
2015-03-27 |
2022-12-30 |
哈佛学院校长同事会 |
经过修饰的t细胞及其制备和使用方法
|
|
JP6921001B2
(ja)
|
2015-04-13 |
2021-08-18 |
ファイザー・インク |
Ｂ細胞成熟抗原を標的にするキメラ抗原受容体
|
|
US10441644B2
(en)
|
2015-05-05 |
2019-10-15 |
The Regents Of The University Of California |
H3.3 CTL peptides and uses thereof
|
|
CN107921148A
(zh)
|
2015-05-08 |
2018-04-17 |
哈佛学院校长同事会 |
通用供体干细胞和相关方法
|
|
MX2017015239A
(es)
*
|
2015-05-29 |
2018-02-19 |
Juno Therapeutics Inc |
Composicion y metodos para regular interacciones inhibitorias en celulas geneticamente modificadas.
|
|
WO2017001572A1
(en)
*
|
2015-06-30 |
2017-01-05 |
Cellectis |
Methods for improving functionality in nk cell by gene inactivation using specific endonuclease
|
|
IL295616A
(en)
|
2015-07-31 |
2022-10-01 |
Us Health |
Adapted cells and treatment methods
|
|
EP4434589A3
(en)
|
2015-10-23 |
2025-05-14 |
President and Fellows of Harvard College |
Evolved cas9 proteins for gene editing
|
|
IL259576B
(en)
|
2015-12-04 |
2022-09-01 |
Novartis Ag |
grna molecule containing tracr and crrna, pharmaceutical composition containing it and method for preparing cells for immunotherapy
|
|
WO2017106528A2
(en)
|
2015-12-18 |
2017-06-22 |
Sangamo Biosciences, Inc. |
Targeted disruption of the t cell receptor
|
|
EA201891641A1
(ru)
|
2016-01-21 |
2019-01-31 |
Пфайзер Инк. |
Химерные антигенные рецепторы, нацеленные на вариант iii рецептора эпидермального фактора роста
|
|
WO2017178585A1
(en)
|
2016-04-15 |
2017-10-19 |
Cellectis |
A method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation
|
|
US11078481B1
(en)
|
2016-08-03 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for screening for cancer targets
|
|
JP7231935B2
(ja)
|
2016-08-03 |
2023-03-08 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
アデノシン核酸塩基編集因子およびそれらの使用
|
|
US11661590B2
(en)
|
2016-08-09 |
2023-05-30 |
President And Fellows Of Harvard College |
Programmable CAS9-recombinase fusion proteins and uses thereof
|
|
MA46059A
(fr)
*
|
2016-08-23 |
2019-07-03 |
Bluebird Bio Inc |
Variants de l'endonucléase homing tim3, compositions et procédés d'utilisation
|
|
WO2018039438A1
(en)
|
2016-08-24 |
2018-03-01 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
|
US11078483B1
(en)
|
2016-09-02 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for measuring and improving CRISPR reagent function
|
|
ES2952525T3
(es)
*
|
2016-09-08 |
2023-11-02 |
2Seventy Bio Inc |
Variantes de endonucleasa homing PD-1, composiciones y métodos de uso
|
|
CN109715199A
(zh)
|
2016-09-14 |
2019-05-03 |
詹森生物科技公司 |
包含bcma特异性iii型纤连蛋白结构域的嵌合抗原受体及其用途
|
|
CA3039797A1
(en)
*
|
2016-10-11 |
2018-04-19 |
Minerva Biotechnologies Corporation |
Humanized anti-muc1* antibodies and use of cleavage enzyme
|
|
AU2017342543B2
(en)
|
2016-10-14 |
2024-06-27 |
President And Fellows Of Harvard College |
AAV delivery of nucleobase editors
|
|
EP4338799A3
(en)
|
2016-10-18 |
2024-06-05 |
Regents of the University of Minnesota |
Tumor infiltrating lymphocytes and methods of therapy
|
|
WO2018073393A2
(en)
|
2016-10-19 |
2018-04-26 |
Cellectis |
Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
|
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
|
TW201839136A
(zh)
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
治療血色素異常症之組合物及方法
|
|
ES2969213T3
(es)
|
2017-02-15 |
2024-05-17 |
2Seventy Bio Inc |
Plantillas de reparación de donantes para edición multiplex del genoma
|
|
CN110662556A
(zh)
|
2017-03-09 |
2020-01-07 |
哈佛大学的校长及成员们 |
癌症疫苗
|
|
US11898179B2
(en)
|
2017-03-09 |
2024-02-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
|
JP2020510439A
(ja)
|
2017-03-10 |
2020-04-09 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
シトシンからグアニンへの塩基編集因子
|
|
CA3054621A1
(en)
|
2017-03-22 |
2018-09-27 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
WO2018176009A1
(en)
|
2017-03-23 |
2018-09-27 |
President And Fellows Of Harvard College |
Nucleobase editors comprising nucleic acid programmable dna binding proteins
|
|
US11560566B2
(en)
|
2017-05-12 |
2023-01-24 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
|
|
US12296012B2
(en)
|
2017-06-02 |
2025-05-13 |
Pfizer Inc. |
Chimeric antigen receptors targeting FLT3
|
|
EP4302768A3
(en)
*
|
2017-06-22 |
2024-05-01 |
Board Of Regents, The University Of Texas System |
Methods for producing regulatory immune cells and uses thereof
|
|
SG10201705285SA
(en)
|
2017-06-27 |
2019-01-30 |
Agency Science Tech & Res |
Antisense oligonucleotides
|
|
EP3645021A4
(en)
|
2017-06-30 |
2021-04-21 |
Intima Bioscience, Inc. |
ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
|
|
CA3067914A1
(en)
|
2017-06-30 |
2019-01-03 |
Cellectis |
Cellular immunotherapy for repetitive administration
|
|
US11161897B2
(en)
|
2017-07-17 |
2021-11-02 |
Janssen Biotech, Inc. |
Antigen binding regions against fibronectin type III domains and methods of using the same
|
|
WO2019016360A1
(en)
|
2017-07-21 |
2019-01-24 |
Cellectis |
MODIFIED IMMUNE CELLS RESISTANT TO TUMOR MICRO-ENVIRONMENT
|
|
US11903968B2
(en)
|
2017-07-21 |
2024-02-20 |
Cellectis |
Engineered immune cells resistant to tumor microenvironment
|
|
US11732274B2
(en)
|
2017-07-28 |
2023-08-22 |
President And Fellows Of Harvard College |
Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
|
|
WO2019139645A2
(en)
|
2017-08-30 |
2019-07-18 |
President And Fellows Of Harvard College |
High efficiency base editors comprising gam
|
|
CA3076337A1
(en)
|
2017-09-19 |
2019-03-28 |
Massachusetts Institute Of Technology |
Compositions for chimeric antigen receptor t cell therapy and uses thereof
|
|
WO2019072824A1
(en)
|
2017-10-09 |
2019-04-18 |
Cellectis |
IMPROVED ANTI-CD123 CAR IN UNIVERSAL MODIFIED IMMUNE T LYMPHOCYTES
|
|
KR20200121782A
(ko)
|
2017-10-16 |
2020-10-26 |
더 브로드 인스티튜트, 인코퍼레이티드 |
아데노신 염기 편집제의 용도
|
|
WO2019078699A2
(ko)
*
|
2017-10-20 |
2019-04-25 |
주식회사 파멥신 |
항-vista 항체 및 이의 용도
|
|
US11326156B2
(en)
|
2017-11-01 |
2022-05-10 |
Allogene Therapeutics, Inc. |
Modified caspase-9 polypeptides and methods of use thereof
|
|
CN111556893A
(zh)
*
|
2017-11-06 |
2020-08-18 |
爱迪塔斯医药股份有限公司 |
免疫疗法t细胞中cblb的crispr-cas9编辑的方法、组合物和组分
|
|
WO2019118508A1
(en)
|
2017-12-12 |
2019-06-20 |
The Trustees Of The University Of Pennsylvania |
Genetically modified immune cells targeting ny-eso-1 and methods of use thereof
|
|
US12406749B2
(en)
|
2017-12-15 |
2025-09-02 |
The Broad Institute, Inc. |
Systems and methods for predicting repair outcomes in genetic engineering
|
|
US20210002621A1
(en)
*
|
2017-12-20 |
2021-01-07 |
Bluebird Bio, Inc. |
Ctla4 homing endonuclease variants, compositions, and methods of use
|
|
WO2019129850A1
(en)
|
2017-12-29 |
2019-07-04 |
Cellectis |
Off-the-shelf engineered cells for therapy
|
|
PE20210708A1
(es)
|
2018-02-01 |
2021-04-16 |
Pfizer |
Anticuerpos especificos para cd70 y sus usos
|
|
IL276396B2
(en)
|
2018-02-01 |
2026-01-01 |
Pfizer |
Chimeric antigen receptors against CD70
|
|
EP3759129A1
(en)
|
2018-02-28 |
2021-01-06 |
Pfizer Inc |
Il-15 variants and uses thereof
|
|
JP2021518160A
(ja)
|
2018-03-15 |
2021-08-02 |
ケーエスキュー セラピューティクス， インコーポレイテッド |
免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法
|
|
AU2019236204B2
(en)
|
2018-03-15 |
2026-02-26 |
KSQ Therapeutics, Inc. |
Gene-regulating compositions and methods for improved immunotherapy
|
|
US12157760B2
(en)
|
2018-05-23 |
2024-12-03 |
The Broad Institute, Inc. |
Base editors and uses thereof
|
|
EP3817767A1
(en)
|
2018-07-02 |
2021-05-12 |
Cellectis |
Chimeric antigen receptors (car)-expressing cells and combination treatment for immunotherapy of patients with relapse refractory adverse genetic risk aml
|
|
US12522807B2
(en)
|
2018-07-09 |
2026-01-13 |
The Broad Institute, Inc. |
RNA programmable epigenetic RNA modifiers and uses thereof
|
|
AU2019327913A1
(en)
|
2018-08-29 |
2021-03-18 |
Nanjing Legend Biotech Co., Ltd. |
Anti-mesothelin chimeric antigen receptor (CAR) constructs and uses thereof
|
|
US12529041B2
(en)
|
2018-09-07 |
2026-01-20 |
Beam Therapeutics Inc. |
Compositions and methods for delivering a nucleobase editing system
|
|
US12454694B2
(en)
|
2018-09-07 |
2025-10-28 |
Beam Therapeutics Inc. |
Compositions and methods for improving base editing
|
|
US12460000B2
(en)
|
2018-09-07 |
2025-11-04 |
Itabmed (Hk) Limited |
Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof
|
|
CA3121855A1
(en)
*
|
2018-09-11 |
2020-03-19 |
Board Of Regents, The University Of Texas System |
A genetic mouse model of autoimmune adverse events and immune checkpoint blockade therapy
|
|
MX2021003435A
(es)
|
2018-09-28 |
2021-06-15 |
Massachusetts Inst Technology |
Moleculas inmunomoduladoras localizadas en el colageno y metodos de las mismas.
|
|
WO2020092453A1
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Nucleobase editors comprising geocas9 and uses thereof
|
|
US20200268797A1
(en)
|
2018-11-30 |
2020-08-27 |
Janssen Biotech, Inc. |
Gamma delta t cells and uses thereof
|
|
US12404500B2
(en)
|
2018-12-10 |
2025-09-02 |
Novo Nordisk A/S |
Homing endonuclease variants
|
|
AU2019395334A1
(en)
|
2018-12-10 |
2021-06-24 |
Regeneron Pharmaceuticals, Inc. |
PDCD-1 homing endonuclease variants
|
|
WO2020132810A1
(en)
|
2018-12-24 |
2020-07-02 |
Generon (Shanghai) Corporation Ltd. |
Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
|
|
WO2020154500A1
(en)
|
2019-01-23 |
2020-07-30 |
The Broad Institute, Inc. |
Supernegatively charged proteins and uses thereof
|
|
WO2020163365A2
(en)
*
|
2019-02-04 |
2020-08-13 |
KSQ Therapeutics, Inc. |
Combination gene targets for improved immunotherapy
|
|
EP3693974A1
(en)
*
|
2019-02-07 |
2020-08-12 |
Koninklijke Philips N.V. |
Identifying responsiveness to radio-immuno combination therapy
|
|
MX2021011426A
(es)
|
2019-03-19 |
2022-03-11 |
Broad Inst Inc |
Metodos y composiciones para editar secuencias de nucleótidos.
|
|
WO2020214842A1
(en)
|
2019-04-17 |
2020-10-22 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
|
US11642409B2
(en)
|
2019-06-26 |
2023-05-09 |
Massachusetts Insttute of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
|
MX2022002363A
(es)
|
2019-08-27 |
2022-06-14 |
Janssen Biotech Inc |
Sistema receptor de antígeno quimérico y usos de este.
|
|
WO2021061648A1
(en)
|
2019-09-23 |
2021-04-01 |
Massachusetts Institute Of Technology |
Methods and compositions for stimulation of endogenous t cell responses
|
|
US12435330B2
(en)
|
2019-10-10 |
2025-10-07 |
The Broad Institute, Inc. |
Methods and compositions for prime editing RNA
|
|
AU2020371562A1
(en)
*
|
2019-10-23 |
2022-06-09 |
The Council Of The Queensland Institute Of Medical Research |
Adoptive immunotherapy
|
|
PE20230173A1
(es)
|
2020-03-03 |
2023-02-01 |
Janssen Biotech Inc |
CELULAS T (gama-delta) Y USOS DE ESTAS
|
|
WO2021183207A1
(en)
|
2020-03-10 |
2021-09-16 |
Massachusetts Institute Of Technology |
COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY OF NPM1c-POSITIVE CANCER
|
|
IL296242A
(en)
|
2020-03-10 |
2022-11-01 |
Massachusetts Inst Technology |
Methods for producing engineered memory-like nk cells and preparations containing them
|
|
US12433954B2
(en)
|
2020-05-01 |
2025-10-07 |
Massachusetts Institute Of Technology |
Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
|
|
US20210340524A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
|
WO2021226558A1
(en)
|
2020-05-08 |
2021-11-11 |
The Broad Institute, Inc. |
Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
|
|
CN116194488A
(zh)
|
2020-07-21 |
2023-05-30 |
艾洛基治疗公司 |
具有增强的信号传导和活性的嵌合抗原受体和其用途
|
|
WO2022067089A1
(en)
|
2020-09-25 |
2022-03-31 |
Beam Therapeutics Inc. |
Fratricide resistant modified immune cells and methods of using the same
|
|
CN116635064A
(zh)
|
2020-12-18 |
2023-08-22 |
世纪治疗股份有限公司 |
具有适应性受体特异性的嵌合抗原受体系统
|
|
AU2022224066A1
(en)
*
|
2021-02-19 |
2023-09-07 |
Angeles Therapeutics, Inc. |
Single-chain and multi-chain synthetic antigen receptors for diverse immune cells
|
|
BR112023018948A2
(pt)
*
|
2021-03-19 |
2023-10-17 |
Metagenomi Inc |
Edição multiplex com enzimas cas
|
|
AR125199A1
(es)
|
2021-03-23 |
2023-06-21 |
Iovance Biotherapeutics Inc |
Edición génica cish de linfocitos infiltrantes de tumores y usos de los mismos en inmunoterapia
|
|
EP4413031A1
(en)
|
2021-10-06 |
2024-08-14 |
Miltenyi Biotec B.V. & Co. KG |
Method for targeted gene insertion into immune cells
|
|
WO2023081715A1
(en)
|
2021-11-03 |
2023-05-11 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
|
EP4502177A4
(en)
|
2022-03-24 |
2026-03-18 |
Nanjing Legend Biotech Co Ltd |
METHOD FOR PREPARING A DNA BANK AND DETECTING A RETROVIRAL INTEGRATION SITE
|
|
EP4504764A1
(en)
|
2022-05-26 |
2025-02-12 |
Caribou Biosciences, Inc. |
Cytokine-receptor fusions for immune cell stimulation
|
|
US20250345424A1
(en)
|
2022-06-06 |
2025-11-13 |
Caribou Biosciences, Inc. |
Treatment of autoimmune diseases with engineered immune cells
|
|
JP2025531877A
(ja)
|
2022-09-09 |
2025-09-25 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
Ｐｄ－１／ｔｉｇｉｔ ｔａｌｅｎダブルノックダウンを使用したｔｉｌ製品を生成するためのプロセス
|
|
EP4583890A1
(en)
|
2022-09-09 |
2025-07-16 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products using pd-1/tigit talen double knockdown
|
|
WO2024088401A1
(en)
*
|
2022-10-28 |
2024-05-02 |
CorrectSequence Therapeutics Co., Ltd |
Gene editing systems and methods for reducing immunogenicity and graft versus host response
|
|
EP4584283A1
(en)
|
2022-11-14 |
2025-07-16 |
Caribou Biosciences, Inc. |
Anti-cll-1 chimeric antigen receptors, engineered cells and related methods
|
|
KR20240076377A
(ko)
|
2022-11-23 |
2024-05-30 |
가톨릭대학교 산학협력단 |
인간 혈청 알부민을 이용한 면역억제 t 세포의 대량 생산 방법
|
|
AU2024265453A1
(en)
|
2023-05-01 |
2025-09-25 |
Caribou Biosciences, Inc. |
Treatment of autoimmune diseases with bcma-targeting engineered immune cells
|
|
WO2025171182A1
(en)
|
2024-02-08 |
2025-08-14 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with cancer vaccine
|
|
WO2025193386A1
(en)
|
2024-03-13 |
2025-09-18 |
Caribou Biosciences, Inc. |
Treatment regimens for autoimmune disease with cd19-targeting engineered immune cells
|